Understanding ASIC3: Potential Drug Target and Biomarker for Neurological Disorders

Target Name: ASIC3

NCBI ID: G9311

ASIC3

Understanding ASIC3: Potential Drug Target and Biomarker for Neurological Disorders

ASIC3 (ASIC3 variant 3) is a protein that is expressed in the brain and plays a crucial role in the development and progression of several neurological disorders, including Alzheimer's disease. The ASIC3 protein has been identified as a potential drug target and a biomarker for several neurological disorders, including Alzheimer's disease.

History of ASIC3

ASIC3 (ASIC3 variant 3) was first identified in the 1990s as a protein that is expressed in the brain and is involved in the development and progression of several neurological disorders, including Alzheimer's disease. Since then, several studies have validated its role in these disorders and identified its potential as a drug target.

Expression of ASIC3

ASIC3 is expressed in the brain and is found in various types of neurons, including astrocytes, oligodendrocytes, and microglia. It is involved in the development and progression of several neurological disorders, including Alzheimer's disease, and has been shown to be involved in the formation of neurofibrillary tangles and the progression of neurodegeneration.

Drug Interactions with ASIC3

Several drugs have been shown to interact with ASIC3, including inhibitors of tyrosine kinase, such as gefitinib and paclitaxel, which have been shown to reduce the expression of ASIC3 in the brain. Other drugs that have been shown to interact with ASIC3 include inhibitors of the protein phosphatase C, such as curacilin, which has been shown to increase the expression of ASIC3 in the brain.

Biomarker Potential

ASIC3 has been identified as a potential biomarker for several neurological disorders, including Alzheimer's disease. Studies have shown that the expression of ASIC3 is increased in the brain of individuals with Alzheimer's disease compared to age-matched individuals without the disease. Additionally, studies have shown that ASIC3 has been associated with the development of neurofibrillary tangles and the progression of neurodegeneration in individuals with Alzheimer's disease.

Targeting ASIC3

ASIC3 is a potential drug target and has been identified as a potential target for several neurodegenerative disorders, including Alzheimer's disease. Drugs that have been shown to target ASIC3 include inhibitors of tyrosine kinase, such as gefitinib and paclitaxel, which have been shown to reduce the expression of ASIC3 in the brain. Other drugs that have been shown to interact with ASIC3 include inhibitors of the protein phosphatase C, such as curacilin, which has been shown to increase the expression of ASIC3 in the brain.

Conclusion

ASIC3 (ASIC3 variant 3) is a protein that is expressed in the brain and plays a crucial role in the development and progression of several neurological disorders, including Alzheimer's disease. It has been identified as a potential drug target and biomarker for these disorders and has has been shown to be involved in the formation of neurofibrillary tangles and the progression of neurodegeneration. Further research is needed to fully understand the role of ASIC3 in these disorders and to develop effective treatments.

Protein Name: Acid Sensing Ion Channel Subunit 3

Functions: Cation channel with high affinity for sodium, which is gated by extracellular protons and inhibited by the diuretic amiloride. Generates a biphasic current with a fast inactivating and a slow sustained phase. In sensory neurons is proposed to mediate the pain induced by acidosis that occurs in ischemic, damaged or inflamed tissue. May be involved in hyperalgesia. May play a role in mechanoreception. Heteromeric channel assembly seems to modulate channel properties

The "ASIC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASIC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets